Thus, inhibiting VEGF and Ang-2 may also enhance the tumor microenvironment to support T cell function, providing a rationale for combining with agents that target the programmed death protein-1 (PD-1) pathway. This evidence concerns the gene ANGPT2 and neoplasm.